NasdaqCM:ATRS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. More Details


Snowflake Analysis

Reasonable growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Antares Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ATRS's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-2.6%

ATRS

-3.8%

US Medical Equipment

-2.5%

US Market


1 Year Return

33.5%

ATRS

27.3%

US Medical Equipment

34.1%

US Market

Return vs Industry: ATRS exceeded the US Medical Equipment industry which returned 27.3% over the past year.

Return vs Market: ATRS matched the US Market which returned 34.1% over the past year.


Shareholder returns

ATRSIndustryMarket
7 Day-2.6%-3.8%-2.5%
30 Day-2.6%0.2%0.1%
90 Day46.5%8.8%4.5%
1 Year33.5%33.5%28.4%27.3%37.1%34.1%
3 Year97.3%97.3%72.0%67.6%58.0%47.9%
5 Year372.9%372.9%154.3%135.4%131.9%106.2%

Long-Term Price Volatility Vs. Market

How volatile is Antares Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Antares Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ATRS ($4.44) is trading below our estimate of fair value ($13.6)

Significantly Below Fair Value: ATRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ATRS is poor value based on its PE Ratio (77.2x) compared to the US Medical Equipment industry average (55.5x).

PE vs Market: ATRS is poor value based on its PE Ratio (77.2x) compared to the US market (21.5x).


Price to Earnings Growth Ratio

PEG Ratio: ATRS is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: ATRS is overvalued based on its PB Ratio (11.3x) compared to the US Medical Equipment industry average (5.1x).


Next Steps

Future Growth

How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

35.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRS's forecast earnings growth (35% per year) is above the savings rate (2%).

Earnings vs Market: ATRS's earnings (35% per year) are forecast to grow faster than the US market (20.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ATRS's revenue (15.5% per year) is forecast to grow faster than the US market (10.5% per year).

High Growth Revenue: ATRS's revenue (15.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Antares Pharma performed over the past 5 years?

45.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRS has high quality earnings.

Growing Profit Margin: ATRS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ATRS has become profitable over the past 5 years, growing earnings by 45.5% per year.

Accelerating Growth: ATRS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ATRS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10%).


Return on Equity

High ROE: ATRS's Return on Equity (14.6%) is considered low.


Next Steps

Financial Health

How is Antares Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ATRS's short term assets ($125.1M) exceed its short term liabilities ($50.6M).

Long Term Liabilities: ATRS's short term assets ($125.1M) exceed its long term liabilities ($39.8M).


Debt to Equity History and Analysis

Debt Level: ATRS's debt to equity ratio (60.6%) is considered high.

Reducing Debt: Insufficient data to determine if ATRS's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ATRS's debt is well covered by operating cash flow (33.1%).

Interest Coverage: ATRS's interest payments on its debt are well covered by EBIT (3.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Antares Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Bob Apple (54 yo)

5.08yrs

Tenure

US$3,514,955

Compensation

Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc. ...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD3.51M) is above average for companies of similar size in the US market ($USD2.21M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Apple
CEO, President & Director5.08yrsUS$3.51m0.96%
$ 7.1m
Fred Powell
Executive VP & CFO4.33yrsUS$1.39m0.25%
$ 1.9m
Peter Graham
Executive VP of Human Resources5.58yrsUS$1.36m0.17%
$ 1.3m
Patrick Madsen
Senior Vice President of Operationsno datano datano data
Keith Muckenhirn
Principal Accounting Officer4.42yrsUS$361.46kno data
Tram Bui
Vice President of Corporate Communications & Investor Relationsno datano datano data
Edward Tykot
Senior Vice President of Corporate Business Development1.17yrsno datano data
Peter Sadowski
Senior Vice President of Technology Portfolio & Intellectual Propertyno dataUS$467.99kno data
Jonathan Jaffe
Interim EVP0.83yrno datano data
Greg Defilippis
Senior Vice President of Device Business & Alliances1.08yrsno datano data
Steven Knapp
Senior Vice President of Regulatory Affairs & Quality Assurance4.92yrsno datano data
Henry Wolfe
Senior Vice President of Product Development4.08yrsno datano data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: ATRS's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Apple
CEO, President & Director5.08yrsUS$3.51m0.96%
$ 7.1m
Robert Roche
Independent Director7.58yrsUS$197.00k0.053%
$ 391.5k
Leonard Jacob
Independent Chairman12.33yrsUS$327.50k0.11%
$ 777.3k
Thomas Garrity
Independent Director17.33yrsUS$217.75k0.12%
$ 862.2k
Anton Gueth
Independent Director17.33yrsUS$221.75k0.23%
$ 1.7m
Peter Greenleaf
Independent Director2.17yrsUS$185.00k0%
$ 0
Karen Smith
Independent Director1.92yrsUS$223.40k0%
$ 0

7.6yrs

Average Tenure

63yo

Average Age

Experienced Board: ATRS's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

Antares Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Antares Pharma, Inc.
  • Ticker: ATRS
  • Exchange: NasdaqCM
  • Founded: 1978
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$740.026m
  • Shares outstanding: 166.67m
  • Website: https://www.antarespharma.com

Number of Employees


Location

  • Antares Pharma, Inc.
  • 100 Princeton South
  • Suite 300
  • Ewing
  • New Jersey
  • 8628
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2001
MJCDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2001

Biography

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company’s injecti...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/24 00:29
End of Day Share Price2021/02/23 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.